Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AERIE PHARMACEUTICALS, INC.

(AERI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

10/12/2021 | 06:38am EST

Item 7.01. Regulation FD Disclosure.

On October 12, 2021, Aerie Pharmaceuticals, Inc. (the "Company") issued a press release announcing positive topline results for the Company's Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% ("netarsudil 0.02%") versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% ("ripasudil 0.4%"). The results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure ("IOP") at week four (p<0.0001), the primary endpoint for the study. A copy of this press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a determination or admission by the Company that this information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:



99.1      Press Release dated October 12, 2021.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about AERIE PHARMACEUTICALS, INC.
11/09Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
11/05Needham Adjusts Price Target on Aerie Pharmaceuticals to $22 From $24, Maintains Buy Ra..
MT
11/05AERIE PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/04Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Busines..
PU
11/04AERIE : Q3 Earnings Snapshot
AQ
11/04AERIE PHARMACEUTICALS INC : Results of Operations and Financial Condition (form 8-K)
AQ
11/04Earnings Flash (AERI) AERIE PHARMACEUTICALS Posts Q3 Revenue $29.3M, vs. Street Est of ..
MT
11/04Earnings Flash (AERI) AERIE PHARMACEUTICALS Reports Q3 Loss $-0.72, vs. Street Est of $..
MT
11/04Aerie Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended Septem..
CI
11/04Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Busines..
BU
More news
Analyst Recommendations on AERIE PHARMACEUTICALS, INC.
More recommendations